ProShare Advisors
ADPT icon

ProShare Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

ProShare Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$545K Sell
25,430
-3,121
-11% -$47.8K ﹤0.01% 1033
2026
Q1 		$396K Sell
28,551
-5,506
-16% -$87.7K ﹤0.01% 1182
2025
Q4 		$553K Buy
34,057
+3,078
+10% +$50.2K ﹤0.01% 1079
2025
Q3 		$463K Sell
30,979
-5,340
-15% -$65.1K ﹤0.01% 1158
2025
Q2 		$423K Buy
36,319
+4,617
+15% +$41.9K ﹤0.01% 1218
2025
Q1 		$236K Sell
31,702
-7,907
-20% -$60.8K ﹤0.01% 1573
2024
Q4 		$237K Buy
39,609
+9,009
+29% +$49.7K ﹤0.01% 1797
2024
Q3 		$157K Buy
30,600
+6,288
+26% +$27.4K ﹤0.01% 1791
2024
Q2 		$88K Sell
24,312
-6,265
-20% -$19.9K ﹤0.01% 1682
2024
Q1 		$98.2K Buy
30,577
+2,525
+9% +$9.77K ﹤0.01% 1822
2023
Q4 		$137K Buy
28,052
+3,838
+16% +$17.5K ﹤0.01% 1730
2023
Q3 		$132K Buy
24,214
+103
+0.4% +$681 ﹤0.01% 1578
2023
Q2 		$162K Buy
24,111
+1,060
+5% +$7.88K ﹤0.01% 1589
2023
Q1 		$204K Sell
23,051
-3,123
-12% -$27.5K ﹤0.01% 1438
2022
Q4 		$200K Buy
26,174
+1,864
+8% +$14.5K ﹤0.01% 1504
2022
Q3 		$173K Buy
24,310
+709
+3% +$6.68K ﹤0.01% 1438
2022
Q2 		$192K Buy
23,601
+8,966
+61% +$78.8K ﹤0.01% 1484
2022
Q1 		$203K Sell
14,635
-5,239
-26% -$82.4K ﹤0.01% 1877
2021
Q4 		$558K Sell
19,874
-10,196
-34% -$313K ﹤0.01% 1371
2021
Q3 		$1.02M Buy
30,070
+4,859
+19% +$176K ﹤0.01% 900
2021
Q2 		$1.03M Buy
25,211
+5,955
+31% +$232K ﹤0.01% 1021
2021
Q1 		$775K Sell
19,256
-1,851
-9% -$100K ﹤0.01% 1140
2020
Q4 		$1.25M Sell
21,107
-776
-4% -$40K ﹤0.01% 793
2020
Q3 		$1.06M Buy
21,883
+1,609
+8% +$67.6K ﹤0.01% 708
2020
Q2 		$981K Buy
20,274
+3,137
+18% +$114K 0.01% 715
2020
Q1 		$476K Sell
17,137
-9,751
-36% -$272K ﹤0.01% 737
2019
Q4 		$804K Buy
+26,888
New +$772K ﹤0.01% 876

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ProShare Advisors's ADPT Position: Q2 2026 in Review

ProShare Advisors reduced its Adaptive Biotechnologies (ADPT) stake by 11% in Q2 2026, selling an estimated $47.8K and leaving 25,430 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #1033.

ProShare Advisors first reported a position in ADPT in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.25M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • ProShare Advisors held 25,430 shares of Adaptive Biotechnologies worth $545K as of Q2 2026.
  • ProShare Advisors sold 3,121 Adaptive Biotechnologies shares in Q2 2026, an estimated $47.8K.
  • Adaptive Biotechnologies made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1033 holding.
  • ProShare Advisors first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 27 quarters since.
  • ProShare Advisors's Adaptive Biotechnologies position peaked at $1.25M in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.